Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiprodil in pediatric GRIN-related neurodevelopmental disorder
NL-OMON59209Phase 3Recruiting
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of radiprodil in GRIN-related disorder (6 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Safety and tolerability, Pharmacokinetics and 3 more. Started Feb 2023; status: recruiting.
02
Drugs
radiprodil
03
Conditions
GRIN-related disorder
Beyond the preview
Go deeper on NL-OMON59209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59209.